<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352612</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00003301</org_study_id>
    <nct_id>NCT00352612</nct_id>
  </id_info>
  <brief_title>Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections</brief_title>
  <official_title>Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aaron Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help define the role of antibiotics in the treatment of
      pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus
      aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a
      penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not
      result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is
      most often susceptible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-associated methicillin resistant Staphylococcus Aureus (CA-MRSA) infections have
      increased significantly over the past decade. Nearly every major region of the country has
      reported infections with this organism, with some areas reporting a prevalence as high as
      80%. Epidemiologic evidence points to the emergence of a new strain of MRSA within the
      community, with unique genetic and clinical characteristics that differentiate it from
      traditional hospital-associated MRSA (HA-MRSA). Unlike HA-MRSA, these CA-MRSA are often
      susceptible in vitro to multiple antibiotic classes (other than penicillins and
      cephalosporins), and often cause significant, deep-seated abscesses in healthy individuals
      without any known risk factors for healthcare contact. Prior to awareness of this disease,
      many clinicians were using penicillin and cephalosporin antibiotics for empiric treatment of
      cutaneous abscesses, yet widespread treatment failures in the face of increasing CA-MRSA
      infections did NOT occur. During a one-year retrospective study in pediatric patients at our
      institution, we found that nearly 50% of CA-MRSA abscesses were treated with &quot;inappropriate&quot;
      antibiotics by susceptibility profiles without any significant adverse outcomes. Many
      clinicians are now confronted with the dilemma of whether to change empiric antibiotic
      therapy to other classes to which CA-MRSA would be expected to be susceptible; the most
      common choices including clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or vancomycin.
      Unfortunately, each of these antibiotics has problems of its own in terms of increased cost,
      poor palatability of pediatric liquid formulation, poorer side effect profile, or necessity
      of IV infusion, and at this time the optimal, empiric antibiotic treatment for presumed
      CA-MRSA skin and soft tissue infections is unclear.

      The purpose of this study is to help define the role of antibiotics in the treatment of
      pediatric skin infections caused by CA-MRSA. We hypothesize that treatment with cephalexin, a
      penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not
      result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is
      most often susceptible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Improvement at the 48-72 Hour Clinical Follow-up</measure>
    <time_frame>48-72 hour clinical follow-up</time_frame>
    <description>Clinical improvement was defined as improvement in at least one of the following four measures without regression in any: (1) erythema (2) pain (3) induration (4) patient or families self report of improvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Staphylococcal Infection</condition>
  <condition>Abscess</condition>
  <condition>Staphylococcal Skin Infection</condition>
  <condition>Folliculitis</condition>
  <arm_group>
    <arm_group_label>cephalexin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clindamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin</intervention_name>
    <description>clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days</description>
    <arm_group_label>clindamycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cephalexin</intervention_name>
    <description>cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days</description>
    <arm_group_label>cephalexin</arm_group_label>
    <other_name>keflex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between the ages of 6 months and 18 years of age (inclusive)

          -  Suspected purulent staphylococcal skin or soft tissue infection

          -  No hospitalization within the previous 14 days

          -  Must have reliable means of follow-up contact (e.g. working phone)

          -  Outpatient management in the judgement of treating physician

        Exclusion Criteria:

          -  Hospitalization on initial visit

          -  Voluntary withdrawal by the treating physician in order to dictate the antibiotic
             being used

          -  Patients with a history of hypersensitivity to or intolerance of cephalexin (or other
             beta lactams) or clindamycin.

          -  Patients with altered immunity (inherited or acquired)

          -  Patients with skin infections related to surgical wounds or hardware.

          -  Patients currently on antibiotic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron E Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf</url>
    <description>Expert Summary of Recommendations for management of MRSA in the community</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <results_first_submitted>April 10, 2012</results_first_submitted>
  <results_first_submitted_qc>April 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2013</results_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Aaron Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>randomized</keyword>
  <keyword>blinded</keyword>
  <keyword>controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Staphylococcal Skin Infections</mesh_term>
    <mesh_term>Folliculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cephalexin</title>
          <description>patients who received cephalexin</description>
        </group>
        <group group_id="P2">
          <title>Clindamycin</title>
          <description>those who received clindamycin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>cephalexin arm</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>clindamycin arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Improvement at the 48-72 Hour Clinical Follow-up</title>
        <description>Clinical improvement was defined as improvement in at least one of the following four measures without regression in any: (1) erythema (2) pain (3) induration (4) patient or families self report of improvement.</description>
        <time_frame>48-72 hour clinical follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cephalexin</title>
            <description>those patients who received cephalexin</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin</title>
            <description>those patients who received clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement at the 48-72 Hour Clinical Follow-up</title>
          <description>Clinical improvement was defined as improvement in at least one of the following four measures without regression in any: (1) erythema (2) pain (3) induration (4) patient or families self report of improvement.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cephalexin</title>
        </group>
        <group group_id="E2">
          <title>Clindamycin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aaron Chen</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4109556143</phone>
      <email>achen33@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

